P/E ratio for Curis (CRIS)
P/E ratio as of April 2024 (TTM): -1.52
According to Curis's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.522. At the end of 2022 the company had a P/E ratio of -0.0451.
P/E ratio history for Curis from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.0451 | -90.53% |
| 2021 | -0.4760 | -22.12% |
| 2020 | -0.6112 | 597.48% |
| 2019 | -0.0876 | 151.46% |
| 2018 | -0.0348 | -68.52% |
| 2017 | -0.1107 | -67.66% |
| 2016 | -0.3422 | 17.6% |
| 2015 | -0.2910 | -18.52% |
| 2014 | -0.3571 | -62.01% |
| 2013 | -0.9400 | 9.62% |
| 2012 | -0.8575 | -56.03% |
| 2011 | -1.95 | -131.52% |
| 2010 | 6.19 | -526.46% |
| 2009 | -1.45 | 486.16% |
| 2008 | -0.2475 | 3.81% |
| 2007 | -0.2384 | -28.28% |
| 2006 | -0.3325 | -47.28% |
| 2005 | -0.6306 | -29.33% |
| 2004 | -0.8923 | -28.81% |
| 2003 | -1.25 | 7013.21% |
| 2002 | -0.0176 | -86.84% |
| 2001 | -0.1339 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 13.7 | -996.88% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 12.2 | -899.36% | 🇺🇸 USA |
 Spectrum Pharmaceuticals
SPPI | -2.86 | 87.98% | 🇺🇸 USA |
 Exelixis EXEL | 79.4 | -5,315.89% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | -16.1 | 954.81% | 🇺🇸 USA |
 Cel-Sci
CVM | -1.95 | 27.99% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | -0.1540 | -89.88% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.